Compare CGEM & CCNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CGEM | CCNE |
|---|---|---|
| Founded | 2016 | 1865 |
| Country | United States | United States |
| Employees | N/A | 950 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.7M | 922.6M |
| IPO Year | 2020 | N/A |
| Metric | CGEM | CCNE |
|---|---|---|
| Price | $16.13 | $31.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 2 |
| Target Price | $30.13 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 956.5K | 73.6K |
| Earning Date | 05-11-2026 | 04-20-2026 |
| Dividend Yield | N/A | ★ 2.51% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $23.21 |
| Revenue Next Year | $5.20 | $7.00 |
| P/E Ratio | ★ N/A | $11.84 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.68 | $21.19 |
| 52 Week High | $16.74 | $31.80 |
| Indicator | CGEM | CCNE |
|---|---|---|
| Relative Strength Index (RSI) | 62.01 | 53.88 |
| Support Level | $11.92 | $29.29 |
| Resistance Level | N/A | $31.52 |
| Average True Range (ATR) | 1.03 | 0.73 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 89.05 | 74.13 |
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
CNB Financial Corp is a Pennsylvania-chartered bank. The bank is a full-service bank engaging in a full range of banking activities and services for individual, business, governmental and institutional customers. These activities and services principally include checking, savings, and time deposit accounts; real estate, commercial, industrial, residential and consumer loans; and a variety of other specialized financial services. Its Private Client Solutions division offers a full range of client services, including private banking and wealth and asset management. The banking segment derives its revenue through the operations as a full-service bank services, including trust and wealth management services, for individual, business, governmental, and institutional customers.